189 related articles for article (PubMed ID: 25196777)
21. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
22. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
23. Selective T-cell depletion for haplotype-mismatched allogeneic stem cell transplantation.
Bastien JP; Roy J; Roy DC
Semin Oncol; 2012 Dec; 39(6):674-82. PubMed ID: 23206844
[TBL] [Abstract][Full Text] [Related]
24. Regulatory T-cell suppression of CD8+ T-cell-mediated graft-versus-host reaction requires their presence during priming.
Wang XN; Haniffa MA; Holtick U; Collin MP; Jackson G; Hilkens CM; Holler E; Edinger M; Hoffmann P; Dickinson AM
Transplantation; 2009 Jul; 88(2):188-97. PubMed ID: 19623013
[TBL] [Abstract][Full Text] [Related]
25. Progress and prospects: graft-versus-host disease.
Mastaglio S; Stanghellini MT; Bordignon C; Bondanza A; Ciceri F; Bonini C
Gene Ther; 2010 Nov; 17(11):1309-17. PubMed ID: 20508597
[TBL] [Abstract][Full Text] [Related]
26. Haploidentical hematopoietic stem cell transplantation with a megadose T-cell-depleted graft: harnessing natural and adaptive immunity.
Aversa F; Martelli MF; Velardi A
Semin Oncol; 2012 Dec; 39(6):643-52. PubMed ID: 23206841
[TBL] [Abstract][Full Text] [Related]
27. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
28. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
Michallet M; Dhedin N; Michallet AS
Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
[TBL] [Abstract][Full Text] [Related]
29. Production of IL-10 by alloreactive sibling donor cells and its influence on the development of acute GVHD.
Weston LE; Geczy AF; Briscoe H
Bone Marrow Transplant; 2006 Jan; 37(2):207-12. PubMed ID: 16284610
[TBL] [Abstract][Full Text] [Related]
30. Pleiotropic approach to graft-versus-host disease.
El-Jawahri A; Chen YB
J Clin Oncol; 2013 Dec; 31(35):4462-4. PubMed ID: 24166516
[No Abstract] [Full Text] [Related]
31. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
[TBL] [Abstract][Full Text] [Related]
32. Total lymphoid irradiation for graft-versus-host disease protection.
Kohrt H; Lowsky R
Curr Opin Oncol; 2009 Jun; 21 Suppl 1():S23-6. PubMed ID: 19561409
[TBL] [Abstract][Full Text] [Related]
33. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
Foss FM
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
[TBL] [Abstract][Full Text] [Related]
34. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
35. [Key players in intestinal GVHD].
Hashimoto D; Teshima T
Rinsho Ketsueki; 2015 Jul; 56(7):807-14. PubMed ID: 26251143
[TBL] [Abstract][Full Text] [Related]
36. Haploidentical bone marrow transplantation without T-cell depletion.
Chang YJ; Huang XJ
Semin Oncol; 2012 Dec; 39(6):653-63. PubMed ID: 23206842
[TBL] [Abstract][Full Text] [Related]
37. Regulatory T cells and IL-17-producing cells in graft-versus-host disease.
Teshima T; Maeda Y; Ozaki K
Immunotherapy; 2011 Jul; 3(7):833-52. PubMed ID: 21751953
[TBL] [Abstract][Full Text] [Related]
38. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
Schwinghammer TL; Bloom EJ
Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
[TBL] [Abstract][Full Text] [Related]
39. How to Make an Immune System and a Foreign Host Quickly Cohabit in Peace? The Challenge of Acute Graft-
Vandenhove B; Canti L; Schoemans H; Beguin Y; Baron F; Graux C; Kerre T; Servais S
Front Immunol; 2020; 11():583564. PubMed ID: 33193397
[TBL] [Abstract][Full Text] [Related]
40. Advances in the prevention of graft-versus-host disease after hematopoietic cell transplantation.
Anasetti C
Transplantation; 2004 May; 77(9 Suppl):S79-83. PubMed ID: 15201691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
